Gilead Sciences Inc. (NASDAQ:GILD) saw a downside of -0.13% to close Friday at $68.05 after subtracting -$0.09 on the day. The 5-day average trading volume is 6,160,740 shares of the company’s common stock. It has gained $69.03 in the past week. An average of 6,818,945 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,366,184.
GILD’s 1-month performance is -3.63% or -$3.83 on its low of $66.88 reached on 10/06/21. The company’s shares have touched a 52-week low of $56.56 and high of $73.34, with the stock’s rally to the 52-week high happening on 08/18/21. YTD, GILD has achieved 16.80% or $9.79. However, the current price is down -7.21%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 17, 55 days have gone by since the last insider trading activity for Gilead Sciences Inc. (GILD). Wilfong Diane E. (SVP, Controller & CAO) most recently sold 13,610 shares at $72.50 per share on Aug 17. This transaction cost the insider $986,725. Chief Commercial Officer, Mercier Johanna, sold 19,496 shares at a price of $66.09 on May 04. Then, on May 03, Director Whitley Richard James sold 20,282 shares at a price of $64.57 per share. This transaction amounted to $1,309,655.
The company’s PE ratio for the last five years has touched a high of 855.75 and a low of 6.599. GILD stock has a beta of 0.41. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.21 while the price-to-book (PB) in the most recent quarter is 4.33, with the price to cash flow ratio at 17.29.
Gilead Sciences Inc. pays an annual dividend of $2.84 per share. Its dividend yield is 4.17% and the payout ratio is 67.60%. GILD’s most recent quarterly dividend payment was made on Sep. 29, when it paid $0.71 a share compared with prior rate of $0.71, down 0.0% from last year’s. The company has boosted its dividend for the last 5 consecutive years with the latest dividend increase of $0.03 reported on Thursday February 4 2021. Measured over the last 3 years, the Dividend has been growing by 30.77% yearly.
It is projected that Gilead Sciences Inc.’s next ex-dividend date will be on 14-Dec. GILD is expected to distribute $0.71 as its next dividend.
Gilead Sciences Inc.’s quick ratio for the period ended June 29 was 1.20, with the current ratio over the same period at 1.40 meaning that GILD stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.42, while the total debt to equity was 1.53. In terms of profitability, the gross margin trailing 12 months is 80.10%. The trailing 12-month EBITDA margin is 48.39% while for the period ending June 29; Gilead Sciences Inc.’s operating margin was 36.70%. The firm’s gross profit as reported stood at $20.12 billion against revenue of $24.69 billion.
For the quarterly period ending June 29 this year, Gilead Sciences Inc.’s cash and short-term investments amounted to $1.63 billion against total debt of $30.18 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 17.28% to $6.22 billion, while revenue of $6.42 billion was -3.31% off the previous quarter. Analysts expected GILD to announce $1.73 per share in earnings in its latest quarter, but it posted $1.87, representing a 8.10% surprise. EBITDA for the quarter stood at more than $2.77 billion. GILD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 48.27 billion, with total debt at $30.18 billion. Shareholders hold equity totaling $1.25 billion
Let’s look briefly at Gilead Sciences Inc. (GILD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 35.30% to suggest the stock is trending Neutral, with historical volatility in this time period at 16.50%.
The stock’s 5-day moving average is $67.73, reflecting a -0.74% or -$0.51 change from its current price. GILD is currently trading -4.14% above its 20-day SMA, -1.16% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -2.55% and +19.39% respectively.
Stochastic %K and %D was 19.06% and 12.79% and the average true range (ATR) pointed at 1.18. The RSI (14) points at 38.17%, while the 14-day stochastic is at 22.08% with the period’s ATR at 1.19. The stock’s 9-day MACD Oscillator is pointing at -0.77 and -1.71 on the 14-day charts.
In the most recent analyst report for Gilead Sciences Inc. (NASDAQ: GILD), RBC Capital Mkts reiterated its an Outperform rating for the company but lifted their price target by $81 to $84. Analysts offering their rating for GILD stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate GILD as a “sell,”, while 13 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 9 have offered a “buy” rating.
What is GILD’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $63.00 and a high of $100.00, with their median price target at $75.00. Looking at these predictions, the average price target given by analysts is for Gilead Sciences Inc. (GILD) stock is $76.08.